A vaccine against the biggest bacterial killer on the planet is a step closer to being available with funding secured for preclinical trials.
Professor James Paton, Director of the University of Adelaide’s Research Centre for Infectious Diseases and his team have been working on a vaccine for Streptococcus pneumoniae (the pneumococcus) that could save two million lives globally a year and address the overuse of antibiotics that leads to resistance.
“The pneumococcus is the biggest bacterial killer on the planet. It’s the most common cause of pneumonia, which is responsible for about 20 per cent of deaths from all causes in children under 5 years in developing countries. Globally, the pneumococcus accounts for about two million deaths a year,” says Professor Paton.
Streptococcus pneumoniae, which is principally spread through close contact with infected but asymptomatic carriers, is the leading cause of sinus and ear infections, meningitis, sepsis and pneumonia. Ear infections are one of the most common childhood illnesses that are habitually treated with antibiotics, contributing to increasing bacterial resistance.
“Vaccinating people against Streptococcus pneumoniae would help to ameliorate the global challenge of increasing bacterial resistance to antibiotics,” says Professor Paton.
“The problem with the existing pneumococcal vaccine is that it targets the outside coat of complex carbohydrates – of which there are 98 structurally distinct types. The current vaccine costs about $150 a dose and only covers 13 types.
“What we have done is to remove this coat to expose all the surface proteins that are common to all pneumococcal types. The body mounts an immune response to these surface proteins if previously exposed or vaccinated.”
Sixteen months ago, Adelaide-based GPN Vaccines Pty Ltd was created to develop this novel “whole bacterial” vaccine (Gamma-PNTM) against Streptococcus pneumoniae. The company has already secured investment from local angel investors as well as a major grant from the National Health & Medical Research Council and a Commercialisation grant from the South Australian Government.
GPN Vaccines has now raised a further AUS$1.1 million from international and Australian-based investors that will be used for preclinical evaluation of the Gamma-PNTM vaccine. Toxicity tests will be carried out as well as the scale-up clinical grade manufacture of the vaccine in readiness for testing in a first-in-human clinical trial.
Learn more: STEP FORWARD FOR PNEUMONIA VACCINE DEVELOPMENT
The Latest on: Pneumonia
via Google News
The Latest on: Pneumonia
- COVID-19 Lung Patterns Show Few Clues for Treating Pneumoniaon March 22, 2020 at 12:14 pm
Doctors are scouring medical reports from hospitals treating the sickest COVID-19 patients for the best advice.
- Coronavirus: 'strange pneumonia' seen in Lombardy in November, leading Italian doctor sayson March 22, 2020 at 10:03 am
Virus was circulating ‘before we were aware of the outbreak in China’, says Giuseppe Remuzzi, director of the Mario Negri Institute for Pharmacological Research Italy has now reported more than 4,800 ...
- Congressman in critical condition with pneumoniaon March 22, 2020 at 7:15 am
A congressman representing a San Francisco Bay Area district is in critical condition after he was hospitalized with pneumonia after he fractured one of his ribs, his chief of staff said on Saturday.
- Congressman Mark DeSaulnier in Critical Condition Following Battle With Pneumoniaon March 22, 2020 at 7:13 am
"The doctors are doing everything they can to care for the Congressman," the representative's office said in a statement.
- Bay Area congressman in critical condition with pneumoniaon March 22, 2020 at 1:45 am
A congressman representing a San Francisco Bay Area district is in critical condition after he was hospitalized with pneumonia after he fractured a rib, his chief of staff said Saturday, U.S. Rep.
- Bay Area congressman Mark DeSaulnier in critical condition with pneumonia after fallon March 21, 2020 at 6:04 pm
A congressman representing a San Francisco Bay Area district is in critical condition after he was hospitalized with pneumonia after he fractured a rib, his chief of staff said Saturday. Rep. Mark ...
- California congressman in critical condition with pneumoniaon March 21, 2020 at 5:53 pm
Rep. Mark DeSaulnier, a California Democrat, is in critical condition and in the hospital for pneumonia after falling during a run, according to his office.
- Rep. DeSaulnier in critical condition due to pneumoniaon March 21, 2020 at 5:15 pm
Rep. Mark DeSaulnier (D-Calif.) is in critical condition due to complications of a non-COVID-19 related pneumonia after fracturing a rib Friday.
- Rep. Mark DeSaulnier declines to 'critical condition' in pneumonia fighton March 21, 2020 at 5:13 pm
Rep. Mark DeSaulnier's condition has deteriorated to critical as the California Democrat battles complications with pneumonia. DeSaulnier, 67, was hospitalized more than a week ago to treat pneumonia ...
- Understanding Pneumonia, a Dangerous Coronavirus Complicationon March 20, 2020 at 2:31 pm
For those who come down with COVID-19, developing pneumonia is a common complication. “Pneumonia is essentially an infection of the lungs,” says Nikita Desai, M.D., a pulmonary and critical care ...
via Bing News